Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni DI Zenzo

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Clinical Immunology (Orlando, Fla.)|June 24, 2008
Multicenter prospective study of the humoral autoimmune response in bullous pemphigoidGiovanni Di Zenzo, Sybille Thoma-Uszynski, Lionel Fontao, et al.
The Journal of Clinical Investigation|September 22, 2012
Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interfaceGiovanni Di Zenzo, Giulia Di Lullo, Davide Corti, et al.
HLA|August 2, 2024
HLA alleles associated to susceptibility to gliptin-associated bullous pemphigoid in Italian patientsMarco Andreani, Feliciana Mariotti, Anna Pira, et al.
American Journal of Medical Genetics. Part A|July 4, 2025
Artificial Intelligence Software Changes Rare Disease Testing Strategy in Real Time: An International Case Series Using Face2GeneNatasha L Rudy, Adriana Gomes, Tinatin Tkemaladze, et al.
Journal of the American Academy of Dermatology|January 1, 2017
Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseasesNina van Beek, Cornelia Dähnrich, Nora Johannsen, et al.
Microorganisms|July 2, 2021
May Bacterial Infections Trigger Bullous Pemphigoid? Case Report and Review of LiteratureMichela Ileen Biondo, Chiara Fiorentino, Severino Persechino, et al.
Frontiers in Medicine|March 17, 2022
Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre StudyCarlo Alberto Maronese, Marzia Caproni, Chiara Moltrasio, et al.
Journal of the American Academy of Dermatology|May 22, 2026
Linagliptin is a risk factor for bullous pemphigoid associated with BP180-NC16A/BP230 seronegativity and milder severity: evidence from a prospective case-control study supporting ECD-BP180 ELISA in reducing diagnostic delayAnna Pira, Adele Salemme, Feliciana Mariotti, et al.
Journal of the American Academy of Dermatology|February 1, 2020
Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technologyNina van Beek, Stine Krüger, Tarek Fuhrmann, et al.
Journal of the American Academy of Dermatology|March 3, 2022
Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter studyAdele Salemme, Luca Fania, Alessandra Scarabello, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Clinical Immunology (Orlando, Fla.)|June 24, 2008
Multicenter prospective study of the humoral autoimmune response in bullous pemphigoidGiovanni Di Zenzo, Sybille Thoma-Uszynski, Lionel Fontao, et al.
The Journal of Clinical Investigation|September 22, 2012
Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interfaceGiovanni Di Zenzo, Giulia Di Lullo, Davide Corti, et al.
HLA|August 2, 2024
HLA alleles associated to susceptibility to gliptin-associated bullous pemphigoid in Italian patientsMarco Andreani, Feliciana Mariotti, Anna Pira, et al.
American Journal of Medical Genetics. Part A|July 4, 2025
Artificial Intelligence Software Changes Rare Disease Testing Strategy in Real Time: An International Case Series Using Face2GeneNatasha L Rudy, Adriana Gomes, Tinatin Tkemaladze, et al.
Journal of the American Academy of Dermatology|January 1, 2017
Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseasesNina van Beek, Cornelia Dähnrich, Nora Johannsen, et al.
Microorganisms|July 2, 2021
May Bacterial Infections Trigger Bullous Pemphigoid? Case Report and Review of LiteratureMichela Ileen Biondo, Chiara Fiorentino, Severino Persechino, et al.
Frontiers in Medicine|March 17, 2022
Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre StudyCarlo Alberto Maronese, Marzia Caproni, Chiara Moltrasio, et al.
Journal of the American Academy of Dermatology|May 22, 2026
Linagliptin is a risk factor for bullous pemphigoid associated with BP180-NC16A/BP230 seronegativity and milder severity: evidence from a prospective case-control study supporting ECD-BP180 ELISA in reducing diagnostic delayAnna Pira, Adele Salemme, Feliciana Mariotti, et al.
Journal of the American Academy of Dermatology|February 1, 2020
Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technologyNina van Beek, Stine Krüger, Tarek Fuhrmann, et al.
Journal of the American Academy of Dermatology|March 3, 2022
Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter studyAdele Salemme, Luca Fania, Alessandra Scarabello, et al.
Pageof 8